Preventing in-hospital cardiac and renal complications in high-risk PCI patients

Jeffrey A Brinker, Charles J. Davidson, Warren Laskey

Research output: Contribution to journalArticle

Abstract

Percutaneous coronary intervention, a highly effective therapy for angina, is associated with in-hospital complications including death, myocardial infarction (MI), emergency coronary artery bypass grafting, stroke, contrast-induced nephropathy (CIN), and vascular access-site problems. Patients with risk factors including advanced age, unstable angina or acute MI, impaired ejection fraction, multivessel disease, peripheral vascular disease, and renal insufficiency (RI) are at increased risk of major adverse cardiac events (MACE). Furthermore, patients with RI, diabetes, congestive heart failure, hypertension, or pre-procedure shock are at increased risk of CIN, which may result in renal failure as well as increased morbidity and mortality from cardiovascular disease. Algorithms have been developed to predict the likelihood of peri-procedural MACE or CIN for individual patients, and at-risk patients should be managed carefully. Measures to avoid MACE include use of antithrombotic therapies such as aspirin, thienopyridines, glycoprotein Gp IIb/IIIa inhibitors, and anticoagulants. In addition, evidence shows that the use of the iso-osmolar, non-ionic, dimeric contrast medium iodixanol may reduce the in-hospital incidences of both MACE (particularly MI) and CIN when compared with the low-osmolar contrast media that it has been tested against. Other approaches to avoid CIN include discontinuation of nephrotoxic drugs, such as non-steroidal anti-inflammatory medications, use of a minimum volume of contrast, provision of intravenous hydration for 24 h beginning before the procedure, and possibly administration of N-acetylcysteine.

Original languageEnglish (US)
JournalEuropean Heart Journal, Supplement
Volume7
Issue numberG
DOIs
StatePublished - Aug 2005

Fingerprint

Renal Insufficiency
Kidney
Myocardial Infarction
Contrast Media
Thienopyridines
Platelet Glycoprotein GPIIb-IIIa Complex
Peripheral Vascular Diseases
Unstable Angina
Acetylcysteine
Percutaneous Coronary Intervention
Coronary Artery Bypass
Anticoagulants
Aspirin
Blood Vessels
Shock
Emergencies
Anti-Inflammatory Agents
Cardiovascular Diseases
Heart Failure
Stroke

Keywords

  • CIN
  • Contrast media
  • Contrast-induced nephropathy
  • MACE
  • Major adverse cardiac events
  • Osmolality
  • Renal insufficiency
  • Risk assessment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Preventing in-hospital cardiac and renal complications in high-risk PCI patients. / Brinker, Jeffrey A; Davidson, Charles J.; Laskey, Warren.

In: European Heart Journal, Supplement, Vol. 7, No. G, 08.2005.

Research output: Contribution to journalArticle

@article{7094db87209b4347b69c45bf9df49c14,
title = "Preventing in-hospital cardiac and renal complications in high-risk PCI patients",
abstract = "Percutaneous coronary intervention, a highly effective therapy for angina, is associated with in-hospital complications including death, myocardial infarction (MI), emergency coronary artery bypass grafting, stroke, contrast-induced nephropathy (CIN), and vascular access-site problems. Patients with risk factors including advanced age, unstable angina or acute MI, impaired ejection fraction, multivessel disease, peripheral vascular disease, and renal insufficiency (RI) are at increased risk of major adverse cardiac events (MACE). Furthermore, patients with RI, diabetes, congestive heart failure, hypertension, or pre-procedure shock are at increased risk of CIN, which may result in renal failure as well as increased morbidity and mortality from cardiovascular disease. Algorithms have been developed to predict the likelihood of peri-procedural MACE or CIN for individual patients, and at-risk patients should be managed carefully. Measures to avoid MACE include use of antithrombotic therapies such as aspirin, thienopyridines, glycoprotein Gp IIb/IIIa inhibitors, and anticoagulants. In addition, evidence shows that the use of the iso-osmolar, non-ionic, dimeric contrast medium iodixanol may reduce the in-hospital incidences of both MACE (particularly MI) and CIN when compared with the low-osmolar contrast media that it has been tested against. Other approaches to avoid CIN include discontinuation of nephrotoxic drugs, such as non-steroidal anti-inflammatory medications, use of a minimum volume of contrast, provision of intravenous hydration for 24 h beginning before the procedure, and possibly administration of N-acetylcysteine.",
keywords = "CIN, Contrast media, Contrast-induced nephropathy, MACE, Major adverse cardiac events, Osmolality, Renal insufficiency, Risk assessment",
author = "Brinker, {Jeffrey A} and Davidson, {Charles J.} and Warren Laskey",
year = "2005",
month = "8",
doi = "10.1093/eurheartj/sui054",
language = "English (US)",
volume = "7",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "G",

}

TY - JOUR

T1 - Preventing in-hospital cardiac and renal complications in high-risk PCI patients

AU - Brinker, Jeffrey A

AU - Davidson, Charles J.

AU - Laskey, Warren

PY - 2005/8

Y1 - 2005/8

N2 - Percutaneous coronary intervention, a highly effective therapy for angina, is associated with in-hospital complications including death, myocardial infarction (MI), emergency coronary artery bypass grafting, stroke, contrast-induced nephropathy (CIN), and vascular access-site problems. Patients with risk factors including advanced age, unstable angina or acute MI, impaired ejection fraction, multivessel disease, peripheral vascular disease, and renal insufficiency (RI) are at increased risk of major adverse cardiac events (MACE). Furthermore, patients with RI, diabetes, congestive heart failure, hypertension, or pre-procedure shock are at increased risk of CIN, which may result in renal failure as well as increased morbidity and mortality from cardiovascular disease. Algorithms have been developed to predict the likelihood of peri-procedural MACE or CIN for individual patients, and at-risk patients should be managed carefully. Measures to avoid MACE include use of antithrombotic therapies such as aspirin, thienopyridines, glycoprotein Gp IIb/IIIa inhibitors, and anticoagulants. In addition, evidence shows that the use of the iso-osmolar, non-ionic, dimeric contrast medium iodixanol may reduce the in-hospital incidences of both MACE (particularly MI) and CIN when compared with the low-osmolar contrast media that it has been tested against. Other approaches to avoid CIN include discontinuation of nephrotoxic drugs, such as non-steroidal anti-inflammatory medications, use of a minimum volume of contrast, provision of intravenous hydration for 24 h beginning before the procedure, and possibly administration of N-acetylcysteine.

AB - Percutaneous coronary intervention, a highly effective therapy for angina, is associated with in-hospital complications including death, myocardial infarction (MI), emergency coronary artery bypass grafting, stroke, contrast-induced nephropathy (CIN), and vascular access-site problems. Patients with risk factors including advanced age, unstable angina or acute MI, impaired ejection fraction, multivessel disease, peripheral vascular disease, and renal insufficiency (RI) are at increased risk of major adverse cardiac events (MACE). Furthermore, patients with RI, diabetes, congestive heart failure, hypertension, or pre-procedure shock are at increased risk of CIN, which may result in renal failure as well as increased morbidity and mortality from cardiovascular disease. Algorithms have been developed to predict the likelihood of peri-procedural MACE or CIN for individual patients, and at-risk patients should be managed carefully. Measures to avoid MACE include use of antithrombotic therapies such as aspirin, thienopyridines, glycoprotein Gp IIb/IIIa inhibitors, and anticoagulants. In addition, evidence shows that the use of the iso-osmolar, non-ionic, dimeric contrast medium iodixanol may reduce the in-hospital incidences of both MACE (particularly MI) and CIN when compared with the low-osmolar contrast media that it has been tested against. Other approaches to avoid CIN include discontinuation of nephrotoxic drugs, such as non-steroidal anti-inflammatory medications, use of a minimum volume of contrast, provision of intravenous hydration for 24 h beginning before the procedure, and possibly administration of N-acetylcysteine.

KW - CIN

KW - Contrast media

KW - Contrast-induced nephropathy

KW - MACE

KW - Major adverse cardiac events

KW - Osmolality

KW - Renal insufficiency

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=31944436967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944436967&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/sui054

DO - 10.1093/eurheartj/sui054

M3 - Article

AN - SCOPUS:31944436967

VL - 7

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - G

ER -